Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

Nicole Wong Doo; Enes Makalic; Jihoon E. Joo; Claire M. Vajdic; Daniel F. Schmidt; Ee Ming Wong; Chol Hee Jung; Gianluca Severi; Daniel J. Park; Jessica Chung; Laura Baglietto; Henry Miles Prince; John F. Seymour; Constantine Tam; John L. Hopper; Dallas R. English; Roger L. Milne; Simon J. Harrison; Melissa C. Southey; Graham G. Giles

doi:10.2217/epi.15.97

Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

Nicole Wong Doo, Enes Makalic, Jihoon E. Joo, Claire M. Vajdic, Daniel F. Schmidt, Ee Ming Wong, Chol Hee Jung, Gianluca Severi, Daniel J. Park, Jessica Chung, Laura Baglietto, Henry Miles Prince, John F. Seymour, Constantine Tam, John L. Hopper, Dallas R. English, Roger L. Milne, Simon J. Harrison, Melissa C. Southey, Graham G. Giles

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

31 Citations (Scopus)

Résumé

Aim: To examine whether peripheral blood methylation is associated with risk of developing mature B-cell neoplasms (MBCNs). Materials and methods: We conducted a case-control study nested within a large prospective cohort. Peripheral blood was collected from healthy participants. Cases of MBCN were identified by linkage to cancer registries. Methylation was measured using the Infinium^® HumanMethylation450. Results: During a median of 10.6-year follow-up, 438 MBCN cases were evaluated. Global hypomethylation was associated with increased risk of MBCN (odds ratio: 2.27, [95% CI: 1.59-3.25]). Within high CpG promoter regions, hypermethylation was associated with increased risk (odds ratio: 1.76 [95% CI: 1.25-2.48]). Promoter hypermethylation was observed in HOXA9 and CDH1 genes. Conclusion: Aberrant global DNA methylation is detectable in peripheral blood collected years before diagnosis and is associated with increased risk of MBCN, suggesting changes to DNA methylation are an early event in MBCN development.

langue originale	Anglais
Pages (de - à)	55-66
Nombre de pages	12
journal	Epigenomics
Volume	8
Numéro de publication	1
Les DOIs	https://doi.org/10.2217/epi.15.97
état	Publié - 1 janv. 2016
Modification externe	Oui

Accès au document

10.2217/epi.15.97

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Wong Doo, N., Makalic, E., Joo, J. E., Vajdic, C. M., Schmidt, D. F., Wong, E. M., Jung, C. H., Severi, G., Park, D. J., Chung, J., Baglietto, L., Prince, H. M., Seymour, J. F., Tam, C., Hopper, J. L., English, D. R., Milne, R. L., Harrison, S. J., Southey, M. C., & Giles, G. G. (2016). Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms. Epigenomics, 8(1), 55-66. https://doi.org/10.2217/epi.15.97

@article{6f8d6c90decb4abaac301cab4e639ccf,

title = "Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms",

abstract = "Aim: To examine whether peripheral blood methylation is associated with risk of developing mature B-cell neoplasms (MBCNs). Materials and methods: We conducted a case-control study nested within a large prospective cohort. Peripheral blood was collected from healthy participants. Cases of MBCN were identified by linkage to cancer registries. Methylation was measured using the Infinium{\textregistered} HumanMethylation450. Results: During a median of 10.6-year follow-up, 438 MBCN cases were evaluated. Global hypomethylation was associated with increased risk of MBCN (odds ratio: 2.27, [95% CI: 1.59-3.25]). Within high CpG promoter regions, hypermethylation was associated with increased risk (odds ratio: 1.76 [95% CI: 1.25-2.48]). Promoter hypermethylation was observed in HOXA9 and CDH1 genes. Conclusion: Aberrant global DNA methylation is detectable in peripheral blood collected years before diagnosis and is associated with increased risk of MBCN, suggesting changes to DNA methylation are an early event in MBCN development.",

keywords = "B-cell neoplasms, DNA methylation, lymphoma, peripheral blood methylation",

author = "{Wong Doo}, Nicole and Enes Makalic and Joo, {Jihoon E.} and Vajdic, {Claire M.} and Schmidt, {Daniel F.} and Wong, {Ee Ming} and Jung, {Chol Hee} and Gianluca Severi and Park, {Daniel J.} and Jessica Chung and Laura Baglietto and Prince, {Henry Miles} and Seymour, {John F.} and Constantine Tam and Hopper, {John L.} and English, {Dallas R.} and Milne, {Roger L.} and Harrison, {Simon J.} and Southey, {Melissa C.} and Giles, {Graham G.}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = jan,

day = "1",

doi = "10.2217/epi.15.97",

language = "English",

volume = "8",

pages = "55--66",

journal = "Epigenomics",

issn = "1750-1911",

number = "1",

}

Wong Doo, N, Makalic, E, Joo, JE, Vajdic, CM, Schmidt, DF, Wong, EM, Jung, CH, Severi, G, Park, DJ, Chung, J, Baglietto, L, Prince, HM, Seymour, JF, Tam, C, Hopper, JL, English, DR, Milne, RL, Harrison, SJ, Southey, MC & Giles, GG 2016, 'Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms', Epigenomics, VOL. 8, Numéro 1, p. 55-66. https://doi.org/10.2217/epi.15.97

TY - JOUR

T1 - Global measures of peripheral blood-derived DNA methylation as a risk factor in the development of mature B-cell neoplasms

AU - Wong Doo, Nicole

AU - Makalic, Enes

AU - Joo, Jihoon E.

AU - Vajdic, Claire M.

AU - Schmidt, Daniel F.

AU - Wong, Ee Ming

AU - Jung, Chol Hee

AU - Severi, Gianluca

AU - Park, Daniel J.

AU - Chung, Jessica

AU - Baglietto, Laura

AU - Prince, Henry Miles

AU - Seymour, John F.

AU - Tam, Constantine

AU - Hopper, John L.

AU - English, Dallas R.

AU - Milne, Roger L.

AU - Harrison, Simon J.

AU - Southey, Melissa C.

AU - Giles, Graham G.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aim: To examine whether peripheral blood methylation is associated with risk of developing mature B-cell neoplasms (MBCNs). Materials and methods: We conducted a case-control study nested within a large prospective cohort. Peripheral blood was collected from healthy participants. Cases of MBCN were identified by linkage to cancer registries. Methylation was measured using the Infinium® HumanMethylation450. Results: During a median of 10.6-year follow-up, 438 MBCN cases were evaluated. Global hypomethylation was associated with increased risk of MBCN (odds ratio: 2.27, [95% CI: 1.59-3.25]). Within high CpG promoter regions, hypermethylation was associated with increased risk (odds ratio: 1.76 [95% CI: 1.25-2.48]). Promoter hypermethylation was observed in HOXA9 and CDH1 genes. Conclusion: Aberrant global DNA methylation is detectable in peripheral blood collected years before diagnosis and is associated with increased risk of MBCN, suggesting changes to DNA methylation are an early event in MBCN development.

AB - Aim: To examine whether peripheral blood methylation is associated with risk of developing mature B-cell neoplasms (MBCNs). Materials and methods: We conducted a case-control study nested within a large prospective cohort. Peripheral blood was collected from healthy participants. Cases of MBCN were identified by linkage to cancer registries. Methylation was measured using the Infinium® HumanMethylation450. Results: During a median of 10.6-year follow-up, 438 MBCN cases were evaluated. Global hypomethylation was associated with increased risk of MBCN (odds ratio: 2.27, [95% CI: 1.59-3.25]). Within high CpG promoter regions, hypermethylation was associated with increased risk (odds ratio: 1.76 [95% CI: 1.25-2.48]). Promoter hypermethylation was observed in HOXA9 and CDH1 genes. Conclusion: Aberrant global DNA methylation is detectable in peripheral blood collected years before diagnosis and is associated with increased risk of MBCN, suggesting changes to DNA methylation are an early event in MBCN development.

KW - B-cell neoplasms

KW - DNA methylation

KW - lymphoma

KW - peripheral blood methylation

UR - http://www.scopus.com/inward/record.url?scp=84954477184&partnerID=8YFLogxK

U2 - 10.2217/epi.15.97

DO - 10.2217/epi.15.97

M3 - Article

C2 - 26679037

AN - SCOPUS:84954477184

SN - 1750-1911

VL - 8

SP - 55

EP - 66

JO - Epigenomics

JF - Epigenomics

IS - 1

ER -